Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AstraZeneca plc (AZN) vs Capri Holdings Ltd (CPRI) Price & Performance

AstraZeneca plcTrade
Capri Holdings LtdTrade

Price performance (Past 24H)

Key statistics

AstraZeneca plc vs Capri Holdings Ltd — how do they compare? AstraZeneca plc trades at $158.33 (market cap $248.14B), while Capri Holdings Ltd trades at $15.64 (market cap $1.75B). The key difference: AstraZeneca plc is far larger — about 141.8× Capri Holdings Ltd's market cap, and AstraZeneca plc pays a 2.01% dividend while Capri Holdings Ltd pays none. Which is the better fit depends on your goals.

AZNCPRI
Market Cap
$248.14B$1.75B
Sector
HealthConsumer Staples
52-Week High
$209.48$27.66
52-Week Low
$147.06$14.98
Enterprise Value
$275.41B$3.03B
Dividend Yield
2.01%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AstraZeneca plc

AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.

Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.

Capri Holdings Ltd

Capri Holdings (CPRI) trades at $15.47, near its 52-week low, with a bearish technical outlook and recent earnings beats overshadowed by declining revenue and a net loss of $1.18 billion in 2025. The company faces challenges in its core Michael Kors brand, with revenue forecasts cut and a high debt-to-asset ratio of 28.79% as of 2025. Despite a consensus price target of $19.60, analyst sentiment is mixed, with 44% buy ratings but significant hold recommendations.

The stock's investment appeal hinges on a successful turnaround, with potential upside from margin improvements and Jimmy Choo growth, but risks include persistent revenue declines, luxury market softness, and execution uncertainties. Near-term volatility is likely as the company navigates brand revamps and inventory issues.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AstraZeneca plc

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.

Read more on AZN

About Capri Holdings Ltd

Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 800 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. John Idol has served as CEO since 2003.

Read more on CPRI